GRAI-MATTER-LABS
4.10.2021 13:04:09 CEST | Business Wire | Press release
GrAI Matter Labs (GML), a pioneer of brain-inspired ultra-low latency computing solutions, and FRAMOS, a leading global imaging provider, will unite at VISION 2021 to create Life-Ready AI for Industrial Vision Platforms. This project is based on FRAMOS’s D435e Industrial Depth Camera and GML's GrAI VIP (Vision Inference Processor) and was formed to advance vision application development in robotics, automation, IoT-connected manufacturing, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005462/en/
The Life-Ready AI for Industrial Vision Platforms will be built on GML's pioneering development of brain-inspired computing techniques for enhanced efficiencies that leverages FRAMOS’s state of the art stereo depth sensing technology for industrial environments through their D435e stereo depth camera. The platform offers full bodied IP66 rated cameras, or board level modules for easy and flexible integration into industrial designs, both with M12 ethernet and M8 power connectors, and are enabled with ultra low latency AI processing for applications such as orientation and tracking for robots; navigation of autonomous transport systems (AGVs); among some of the many possibilities.
GML and FRAMOS will showcase the integration of the Life-Ready AI platform and D435e Industrial Depth Camera at the Vision 2021 in Stuttgart, Germany, taking place over three days starting October 5th .
“We are proud to be working with FRAMOS to couple GML's "Life-Ready AI" chips, state-of-the-art brain-inspired computing architecture, and FRAMOS' robust D400e depth camera series, to enable many types of new low latency applications in industrial manufacturing that will allow us to bring AI processing closer to where data is generated. This collaboration enables us to realize the full potential of end-point AI, allowing for actionable insights into manufacturing operations to improve productivity and lower costs,” said Christian Verbrugge, GML Europe - Senior Director Business Development.
Ferdinand Reitze, FRAMOS Product Manager 3D, is delighted about the integration, saying: “GML successfully reduced the footprint of AI inference at the edge, while achieving best results, speed and low latency. Together with our D400e series, the Life-Ready AI chips will enable new ways to resolve todays and tomorrows challenges in robotics and automation for our customers.”
About GrAI Matter Labs
At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans. AI that makes machines act and react in real-time. AI that optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by a team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.
For more information, please visit www.graimatterlabs.ai .
About FRAMOS
FRAMOS® is an imaging expert, trusted advisor, and vision solutions provider. Since 1981 FRAMOS implements the best current and emerging imaging technologies for specific customer requirements and applications. FRAMOS meets these requirements with advanced and proven imaging components from a global network of renowned partners, and proprietary IP.
More than 170 FRAMOS employees world-wide are passionate about the unlimited potential of imaging and help customers achieve the optimum results from every possible scenario. FRAMOS drives and ensures the entire product development journey. This journey starts with the careful selection of imaging components, like image sensors, lenses, through various 3D technologies, to custom development tailored to individual needs and time frames. FRAMOS listens and understands customer challenges. With innovative solutions FRAMOS ensures successful project outcomes and develops long-term customer relations.
For more information, please visit www.framos.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom